Long-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results and Demonstrates Superior Two- and Four-Year Survival Rates

Patients treated with Optune® together with temozolomide demonstrated a significant increase in progression free and overall survival compared to patients treated with temozolomide alone ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that a long-term analysis of the full trial cohort from its phase 3 pivotal EF-14 trial of Optune® in combination with temozolomide for the …

Novocure Presents Interim STELLAR Results at IASLC Suggesting Treatment with Tumor Treating Fields Plus Chemotherapy may Extend Survival of Patients with Mesothelioma

One-year survival rates of patients treated with Tumor Treating Fields combined with pemetrexed and cisplatin or carboplatin were more than 58% greater than historical control data ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that data will be presented from STELLAR, its ongoing phase 2 pilot clinical trial in mesothelioma, at the International Association for …

Novocure Sponsors Pulitzer Prize-Winning Author Dr. Siddhartha Mukherjee as Keynote Speaker of 21st Annual Scientific Meeting of the Society for Neuro-Oncology

Dr. Mukherjee wrote Pulitzer Prize-Winning book The Emperor of All Maladies and New York Times bestseller The Gene. ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that it has sponsored Pulitzer Prize-winning author Dr. Siddhartha Mukherjee as the keynote speaker of the 21st Annual Scientific Meeting of the Society for Neuro-Oncology on Nov. 19, 2016, in …

Novocure Announces 38 Presentations on Tumor Treating Fields at 21st Annual Scientific Meeting of the Society of Neuro-Oncology

28 of 38 abstracts were prepared by external researchers, representing increasing interest in Novocure’s proprietary therapy ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that 38 abstracts focusing on Tumor Treating Fields (TTFields) will be presented at the 21st Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) on Nov. 17-20, in Scottsdale, Arizona. Of the …

United Healthcare Issues Positive Coverage Decision for Optune

As of Jan. 1, 2017, more than 177 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that United Healthcare will cover Optune as an adjunctive therapy for the treatment of glioblastoma (GBM) when used according to FDA labeled indications and …

Novocure Reports Third Quarter 2016 Financial Results and Provides Company Update

Three months ended ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a proprietary therapy for solid tumors, today reported financial results for the quarter ended September 30, 2016, highlighting year-over-year and sequential growth in prescriptions, active patients and revenues. Third quarter 2016 highlights include:     Three months ended Nine months …

Novocure Recognizes National Family Caregivers Month by Supporting GBM Heroes Event

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will promote programs that support the glioblastoma (GBM) community during National Family Caregivers Month in November. Novocure will sponsor CURE magazine’s 2nd Annual GBM Heroes Recognition program, which honors those who have made a difference in the lives of people with the disease. The event, …